Literature DB >> 23624627

Adenylyl cyclase type 5 in cardiac disease, metabolism, and aging.

Stephen F Vatner1, Misun Park, Lin Yan, Grace J Lee, Lo Lai, Kousaku Iwatsubo, Yoshihiro Ishikawa, Jeffrey Pessin, Dorothy E Vatner.   

Abstract

G protein-coupled receptor/adenylyl cyclase (AC)/cAMP signaling is crucial for all cellular responses to physiological and pathophysiological stimuli. There are nine isoforms of membrane-bound AC, with type 5 being one of the two major isoforms in the heart. Since the role of AC in the heart in regulating cAMP and acute changes in inotropic and chronotropic state are well known, this review will address our current understanding of the distinct regulatory role of the AC5 isoform in response to chronic stress. Transgenic overexpression of AC5 in cardiomyocytes of the heart (AC5-Tg) improves baseline cardiac function but impairs the ability of the heart to withstand stress. For example, chronic catecholamine stimulation induces cardiomyopathy, which is more severe in AC5-Tg mice, mediated through the AC5/sirtuin 1/forkhead box O3a pathway. Conversely, disrupting AC5, i.e., AC5 knockout, protects the heart from chronic catecholamine cardiomyopathy as well as the cardiomyopathies resulting from chronic pressure overload or aging. Moreover, AC5 knockout results in a 30% increase in a healthy life span, resembling the most widely studied model of longevity, i.e., calorie restriction. These two models of longevity share similar gene regulation in the heart, muscle, liver, and brain in that they are both protected against diabetes, obesity, and diabetic and aging cardiomyopathy. A pharmacological inhibitor of AC5 also provides protection against cardiac stress, diabetes, and obesity. Thus AC5 inhibition has novel, potential therapeutic applicability to several diseases not only in the heart but also in aging, diabetes, and obesity.

Entities:  

Keywords:  AC5 inhibitor; adenylyl cyclase type 5; aging; cardiomyopathy; metabolism

Mesh:

Substances:

Year:  2013        PMID: 23624627      PMCID: PMC3727099          DOI: 10.1152/ajpheart.00080.2013

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  84 in total

Review 1.  Tissue specificity and physiological relevance of various isoforms of adenylyl cyclase.

Authors:  N Defer; M Best-Belpomme; J Hanoune
Journal:  Am J Physiol Renal Physiol       Date:  2000-09

2.  PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts.

Authors:  S O Marx; S Reiken; Y Hisamatsu; T Jayaraman; D Burkhoff; N Rosemblit; A R Marks
Journal:  Cell       Date:  2000-05-12       Impact factor: 41.582

Review 3.  Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part III: cellular and molecular clues to heart and arterial aging.

Authors:  Edward G Lakatta
Journal:  Circulation       Date:  2003-01-28       Impact factor: 29.690

4.  Effects of cardiac overexpression of type 6 adenylyl cyclase affects on the response to chronic pressure overload.

Authors:  Aziz Guellich; Shumin Gao; Chull Hong; Lin Yan; Thomas E Wagner; Sunil K Dhar; Bijan Ghaleh; Luc Hittinger; Kosaku Iwatsubo; Yoshihiro Ishikawa; Stephen F Vatner; Dorothy E Vatner
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-06-18       Impact factor: 4.733

Review 5.  Toward a unified theory of caloric restriction and longevity regulation.

Authors:  David A Sinclair
Journal:  Mech Ageing Dev       Date:  2005-09       Impact factor: 5.432

6.  Beta-adrenoceptor desensitization during the development of canine pacing-induced heart failure.

Authors:  D E Vatner; N Sato; Y Ishikawa; K Kiuchi; R P Shannon; S F Vatner
Journal:  Clin Exp Pharmacol Physiol       Date:  1996-08       Impact factor: 2.557

7.  Altered calcium handling is critically involved in the cardiotoxic effects of chronic beta-adrenergic stimulation.

Authors:  Stefan Engelhardt; Lutz Hein; Vitaly Dyachenkow; Evangelia G Kranias; Gerrit Isenberg; Martin J Lohse
Journal:  Circulation       Date:  2004-02-16       Impact factor: 29.690

Review 8.  What is the role of beta-adrenergic signaling in heart failure?

Authors:  Martin J Lohse; Stefan Engelhardt; Thomas Eschenhagen
Journal:  Circ Res       Date:  2003-11-14       Impact factor: 17.367

9.  Inhibition of lipolysis by palmitate, H2O2 and the sulfonylurea drug, glimepiride, in rat adipocytes depends on cAMP degradation by lipid droplets.

Authors:  Günter Müller; Susanne Wied; Sabine Over; Wendelin Frick
Journal:  Biochemistry       Date:  2008-01-11       Impact factor: 3.162

10.  High fat diet enhances cardiac abnormalities in SHR rats: Protective role of heme oxygenase-adiponectin axis.

Authors:  Jian Cao; Komal Sodhi; Nitin Puri; Sumit R Monu; Rita Rezzani; Nader G Abraham
Journal:  Diabetol Metab Syndr       Date:  2011-12-23       Impact factor: 3.320

View more
  26 in total

1.  Adenylyl cyclase 5 links changes in calcium homeostasis to cAMP-dependent cyst growth in polycystic liver disease.

Authors:  Carlo Spirli; Valeria Mariotti; Ambra Villani; Luca Fabris; Romina Fiorotto; Mario Strazzabosco
Journal:  J Hepatol       Date:  2016-11-05       Impact factor: 25.083

2.  A novel adenylyl cyclase type 5 inhibitor that reduces myocardial infarct size even when administered after coronary artery reperfusion.

Authors:  Jie Zhang; Daniel Levy; Marko Oydanich; Claudio A Bravo; Seonghun Yoon; Dorothy E Vatner; Stephen F Vatner
Journal:  J Mol Cell Cardiol       Date:  2018-05-22       Impact factor: 5.000

3.  Cross-Talk Between the Adenylyl Cyclase/cAMP Pathway and Ca2+ Homeostasis.

Authors:  Jose Sanchez-Collado; Jose J Lopez; Isaac Jardin; Gines M Salido; Juan A Rosado
Journal:  Rev Physiol Biochem Pharmacol       Date:  2021       Impact factor: 5.545

4.  A Type 2 Diabetes-Associated Functional Regulatory Variant in a Pancreatic Islet Enhancer at the ADCY5 Locus.

Authors:  Tamara S Roman; Maren E Cannon; Swarooparani Vadlamudi; Martin L Buchkovich; Brooke N Wolford; Ryan P Welch; Mario A Morken; Grace J Kwon; Arushi Varshney; Romy Kursawe; Ying Wu; Anne U Jackson; Michael R Erdos; Johanna Kuusisto; Markku Laakso; Laura J Scott; Michael Boehnke; Francis S Collins; Stephen C J Parker; Michael L Stitzel; Karen L Mohlke
Journal:  Diabetes       Date:  2017-07-06       Impact factor: 9.461

Review 5.  Unbalanced Growth, Senescence and Aging.

Authors:  Michael Polymenis; Brian K Kennedy
Journal:  Adv Exp Med Biol       Date:  2017       Impact factor: 2.622

Review 6.  International Union of Basic and Clinical Pharmacology. CI. Structures and Small Molecule Modulators of Mammalian Adenylyl Cyclases.

Authors:  Carmen W Dessauer; Val J Watts; Rennolds S Ostrom; Marco Conti; Stefan Dove; Roland Seifert
Journal:  Pharmacol Rev       Date:  2017-04       Impact factor: 25.468

7.  Overexpression of adenylyl cyclase type 5 (AC5) confers a proarrhythmic substrate to the heart.

Authors:  Zhenghang Zhao; Gopal J Babu; Hairuo Wen; Nadezhda Fefelova; Richard Gordan; Xiangzhen Sui; Lin Yan; Dorothy E Vatner; Stephen F Vatner; Lai-Hua Xie
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-12-05       Impact factor: 4.733

Review 8.  Calcific Aortic Valve Disease: Part 2-Morphomechanical Abnormalities, Gene Reexpression, and Gender Effects on Ventricular Hypertrophy and Its Reversibility.

Authors:  Ares Pasipoularides
Journal:  J Cardiovasc Transl Res       Date:  2016-05-16       Impact factor: 4.132

Review 9.  The role of Epac in the heart.

Authors:  Takayuki Fujita; Masanari Umemura; Utako Yokoyama; Satoshi Okumura; Yoshihiro Ishikawa
Journal:  Cell Mol Life Sci       Date:  2016-08-22       Impact factor: 9.261

10.  Inhibitors of membranous adenylyl cyclases with affinity for adenosine receptors.

Authors:  Karl-Norbert Klotz; Sonja Kachler
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2015-12-14       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.